Trial Profile
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs SUN 13837 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Asubio Pharmaceuticals; Daiichi Sankyo Inc
- 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to enrolment.
- 11 Oct 2014 New trial record